Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Licensing
-
By Jason Derry — Nature Reviews Drug Discovery has published an article relating to potential pitfalls associated with licensing deals between pharmaceutical companies and biotechnology companies. In particular, the authors discuss the financial considerations of trying to in-license a biotech product in the early stages of clinical development. The article reviews strategies that…
-
By Jason Derry — MedImmune, Inc. and Biowa, Inc. have announced a licensing and collaboration deal relating to development and commercialization of therapies for inflammatory diseases. In particular, the agreement relates to treatments that target interleukin-5 receptor. The companies have indicated that the initial focus will be on a monoclonal antibody, BIW-8405, which…
-
By Jason Derry — Alfacell Corp. and GENESIS Pharma S.A. have announced an exclusive licensing deal involving Alfacell's lead compound, ONCONASE®. The compound is in Phase IIIb clinical trials for the treatment of unresectable malignant mesothelioma. Under the agreement, GENESIS will receive the exclusive right to market and distribute ONCONASE® in Southeast Europe. Alfacell…
-
By Jason Derry — Genentech and AC Immune have announced a $300 million licensing agreement relating to the development of antibodies for treating Alzheimer's disease. AC Immune's research in the Alzheimer's area includes inducing anti-beta amyloid antibody production in patients. The announcement marks the third recent major licensing deal between Genentech and a…
-
By Jason Derry — Targeted Genetics Corp. has announced a non-exclusive licensing deal with Amsterdam Molecular Therapeutics B.V. relating to the use of the AAV1 (Adeno-Associated Virus Type 1) vector. The licensed AAV1 vector is covered by U.S. Patent Nos. 6,759,237 and 7,105,345. AMT intends to use the vector for developing therapeutics for…
-
By Jason Derry — As reported by the San Diego Union Tribune, the Scripps Research Institute and Pfizer Inc. have agreed on a 5 year, $100 million partnership. The arrangement provides Pfizer the option of licensing up to 47% of the discoveries made at Scripps over the next 5 years, while Scripps receives…
-
By Jason Derry — The Philadelphia Inquirer reported today that Delaware has instituted a new agency to receive donated patents with the goal of inspiring economic growth within the State. The agency hopes to generate Delaware-based companies through licensing of its available patents. The agency currently has over 250 patents from DuPont Co.…
-
By Jason Derry — Can the open source problem-solving model used in the software community work in the world of science? The Harvard Business School has published a very interesting interview on this topic (see "Open Source Science: A New Model for Innovation"). In the interview, Karim R. Lakhani, assistant professor at the…
-
By Kevin Noonan — Several years ago, it became current among certain academic commentators to opine that patenting genes could become a "tragedy of the anticommons." By this they meant that permitting gene patenting would restrict progress, inhibit academic freedom and prevent scientists from working cooperatively. Significantly, most of these commentators had neither…
Patent Docs 